Additionally, small-scale VS was conducted to test the predictability of our VS protocol for identifying PPARγ full agonists in the hopes of finding natural therapeutics and/or prophylactics for treating IBD and other chronic inflammation-related diseases. The gene discussed is PPARG; the disease is inflammatory bowel disease.